Wells Fargo
RARE icon

Wells Fargo’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wells Fargo’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$15K – 7350
2022
Q1 		$15K Hold
200
– – ﹤0.01% 6130
2021
Q4 		$17K Buy
+200
New +$16.3K ﹤0.01% 6382
2019
Q3 		– Sell
-76,500
Closed -$124K – 6641
2019
Q2 		$124K Buy
+76,500
New +$4.87M ﹤0.01% 5213

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Wells Fargo's RARE Position: Q2 2026 in Review

Wells Fargo increased its Ultragenyx Pharmaceutical (RARE) stake by 129% in Q2 2026, buying an estimated $2.21M and bringing the position to 157,643 shares worth $5.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

Wells Fargo first reported a position in RARE in Q1 2014 and has held it in 50 quarters since. The position peaked at $199M in Q4 2015. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Wells Fargo held 157,643 shares of Ultragenyx Pharmaceutical worth $5.26M as of Q2 2026.
  • Wells Fargo bought 88,878 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.21M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2793 holding.
  • Wells Fargo first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 50 quarters since.
  • Wells Fargo's Ultragenyx Pharmaceutical position peaked at $199M in Q4 2015.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.